Oscar Health OSCR Q1 2026 Earnings Transcript

Oscar Health delivered record Q1 2026 results, with revenue up 53% year over year to $4.6 billion, net income of $679 million, and operating income of $704 million. Margins improved sharply as MLR fell 490 bps to 70.5% and SG&A improved 60 bps to 15.2%, while membership rose 56% to 3.2 million. Management reaffirmed full-year 2026 guidance and highlighted AI-driven operating leverage plus new product launches, including the Lucie Health Marketplace and ICHRA X.

Analysis

OSCR’s print is less about one-quarter earnings power and more about the company proving it can turn a volatile, subsidy-dependent model into a compounding operating platform. The key second-order takeaway is that AI is not just reducing unit costs; it is improving quote-to-bind, member servicing, and broker workflow, which should keep CAC low even as the market normalizes. That matters because the business is now showing operating leverage from both sides of the P&L: better acquisition economics and lower friction in servicing the book.

The market is likely underappreciating how much of the current beat is a function of unusually strong underwriting timing rather than a one-off claims gift. Risk adjustment running hot early is not itself bullish; the real bull case is that management believes their reserve posture still excludes a potentially favorable morbidity backdrop later in the year. If that proves out in the June/July data, OSCR can get a double unlock: lower RA drag plus higher confidence in 2027 pricing, which is the setup for multiple expansion rather than just EPS revision.

The bear case is that this is peak optics before utilization seasonally rises and the company hands back some of the first-half advantage. A normalized churn environment and the unwind of subsidy-related distortions could expose whether growth is truly durable or just market-share capture from stressed competitors. The biggest hidden risk is that investors may extrapolate current operating margins into a full-year run-rate before the second and third-quarter claims seasonality resets expectations.

Lucie and ICHRA X are strategically important but should be viewed as option value, not near-term EPS contributors. The more interesting implication is that OSCR is building a distribution layer that could eventually monetize outside the ACA, which widens the addressable market and reduces dependence on annual open enrollment. That makes the stock a more credible multi-year compounder, but only if execution remains clean through the next two morbidity checkpoints.

Key Decisions for Investors

• Long OSCR for a 2-4 month tactical trade into the June Wakely update and Q2 claims season; target a re-rating if RA moderates and the company confirms its 20% full-year assumption. Use a tight stop if utilization inflects or the next data point shows market morbidity is not favorable.
• Buy OSCR January 2027 calls or call spreads to express the view that 2026 is an inflection year for both underwriting and platform monetization. The convexity is attractive because the upside case is multiple expansion, not just earnings growth.
• Pair trade: long OSCR / short AFL over the next 1-2 quarters. OSCR has the cleaner near-term operating leverage and stronger optionality from tech/distribution innovation, while AFL is more exposed to slower-moving benefits dynamics.
• If already long OSCR common, finance part of the position by selling near-dated covered calls into strength after the stock reacts to the earnings beat. The setup is strong but sentiment is likely to overshoot before Q2 data either confirms or fades the margin story.
• Avoid chasing after a one-day pop; add on any post-earnings consolidation because the cleaner entry is likely after the market prices in the seasonal MLR ramp rather than before it.